Dr. Robert Nussenblatt, world-class ocular immunologist and expert in clinical research design and conduct, gives an update on new therapies for ocular inflammatory disease. Medications widely used for other indications — including medications directed against inflammation mediators such as B cells, interleukin-1, interleukin-6, and mTOR inhibitors — are under evaluation for treatment of ocular inflammatory disease. The discovery of new signaling pathways such as Janus kinase-signal transducer and STAT signaling pathways also provide new targets for therapy. Other therapies include dendritic cell and T-regulatory therapy, oral tolerance, and epigenetic therapy.